Zaitoon Hussein, Garkaby Jenny, Nassrallah Basheer, Sharkansky Livnat, Shnaider Morya, Chistyakov Irina, Genizi Jacob, Nathan Keren
Department of Pediatrics, Bnai Zion Medical Center, Haifa 3104802, Israel.
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
Children (Basel). 2024 Sep 20;11(9):1142. doi: 10.3390/children11091142.
The escalating resistance of uropathogens in pediatric febrile urinary tract infection (F-UTI) is a global concern. This study examined changing trends in F-UTI epidemiology and resistance patterns among Israeli pediatric inpatients over a decade. Demographic, clinical, and laboratory data for children between 3 months and 18 years old with febrile UTI from 2010 to 2021 were retrieved from electronic medical records. A total of 761 cases of F-UTI were identified (702 females, mean age 43 months). was the most common pathogen (85.9%), followed by (3.5%) and (3.4%). Compared with the non-complicated UTI group, the complicated UTI group had significantly higher rates of (5.3% vs. 1.0%, = 0.002) and (4.6% vs. 1.6%, = 0.03). Antibiotic resistance analysis revealed significant differences between the groups: resistance to cephalexin was higher in the complicated UTI group (19.3%) compared with the non-complicated UTI group (13.4%, = 0.03). Notably, relatively low resistance rates were observed for ceftriaxone (4.4%) and gentamicin (6.0%). Over time, a significant decreasing trend in resistance to ampicillin was observed (slope = -0.0193, = 0.011). No significant trends were found for trimethoprim-sulfamethoxazole, cephalexin, amoxicillin-clavulanic acid, ceftriaxone, and cefuroxime. Significant differences in pathogen distribution and resistance patterns between complicated UTI and non-complicated UTI groups highlight the need for continuous resistance monitoring and adherence to local guidelines. For the treatment of severe community F-UTI, ceftriaxone could be a reasonable option for first-onset F-UTI. Further studies are needed to implement antibiotic stewardship and optimize usage.
小儿发热性尿路感染(F-UTI)中尿路病原体耐药性的不断升级是一个全球关注的问题。本研究调查了以色列儿科住院患者十年来F-UTI流行病学和耐药模式的变化趋势。从电子病历中检索了2010年至2021年3个月至18岁发热性UTI儿童的人口统计学、临床和实验室数据。共确定761例F-UTI病例(702例女性,平均年龄43个月)。 是最常见的病原体(85.9%),其次是 (3.5%)和 (3.4%)。与非复杂性UTI组相比,复杂性UTI组的 发生率显著更高(5.3%对1.0%, = 0.002)和 (4.6%对1.6%, = 0.03)。抗生素耐药性分析显示两组之间存在显著差异:复杂性UTI组对头孢氨苄的耐药性(19.3%)高于非复杂性UTI组(13.4%, = 0.03)。值得注意的是,观察到头孢曲松(4.4%)和庆大霉素(6.0%)的耐药率相对较低。随着时间的推移,观察到对氨苄西林的耐药性呈显著下降趋势(斜率 = -0.0193, = 0.011)。对于甲氧苄啶-磺胺甲恶唑、头孢氨苄、阿莫西林-克拉维酸、头孢曲松和头孢呋辛,未发现显著趋势。复杂性UTI组和非复杂性UTI组之间病原体分布和耐药模式的显著差异凸显了持续耐药监测和遵守当地指南的必要性。对于严重社区F-UTI的治疗,头孢曲松可能是初发性F-UTI的合理选择。需要进一步研究以实施抗生素管理并优化使用。